| Bioactivity | Peruvoside is a potent inhibitor of Src, PI3K, JNK, STAT, and EGFR. Peruvoside induces apoptosis and autophagy and possesses a broad spectrum of anticancer activity in breast, lung, liver cancers and leukemia. Peruvoside is a broad-spectrum and potent antiviral activity against positive-sense RNA viruses. Peruvoside sensitizes Gefitinib (HY-50895)-resistant tumour cells (A549, PC9/gef and H1975) to Gefitinib[1][2][3][4]. |
| Invitro | Peruvoside (50-5000 nM，24 小时) 抑制了 PC9，PC9/gef，H3255，和 H1975 细胞系的活力和增殖[1]。Peruvoside (0.005-0.5 μM, 72 小时) 与 Gefitinib (0.01~0.5 μM) 联用时，增强了 A549， PC9/gef 和 H1975 细胞对 Gefitinib 的敏感程度[1]。Peruvoside (0-100 μM，24 小时) 诱导 MCF-7，HpG2 和 A549 细胞的周期停滞和凋亡[2。 0 --> Peruvoside 相关抗体: Cell Proliferation Assay[1] Cell Line: |
| In Vivo | Peruvoside (0.1 mg/kg，腹腔注射；一天一次，连续 28 天) 抑制肺癌小鼠模型的肿瘤生长[1]。Peruvoside (0.59 mg/kg，腹腔注射；一天一次，连续 7 天) 降低了 EV-A71 感染小鼠模型的死亡率[4]。 Animal Model: |
| Name | Peruvoside |
| CAS | 1182-87-2 |
| Formula | C30H44O9 |
| Molar Mass | 548.66 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lai Y, et al. Peruvoside is a novel Src inhibitor that suppresses NSCLC cell growth and motility by downregulating multiple Src-EGFR-related pathways. Am J Cancer Res. 2022 Jun 15;12(6):2576-2593. [2]. Reddy D, et al. Peruvoside targets apoptosis and autophagy through MAPK Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways in human cancers. Life Sci. 2020 Jan 15;241:117147. doi: 10.1016/j.lfs.2019.117147. Epub 2019 Dec 9. PMID: 31830480. [3]. Feng Q, et al. Peruvoside, a Cardiac Glycoside, Induces Primitive Myeloid Leukemia Cell Death. Molecules. 2016 Apr 22;21(4):534. [4]. Wu KX, et al. The host-targeting compound peruvoside has a broad-spectrum antiviral activity against positive-sense RNA viruses. Acta Pharm Sin B. 2023 May;13(5):2039-2055. |